Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES414 in mCRPC
NCT02262910Phase 1Completed
- Sponsor
- Aptevo Therapeutics
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MOR209 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Aptevo Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2015; status: completed.
02
Drugs
MOR209
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02262910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262910.